Bistos gets $2.3M lifeline from top shareholder in listing-defence push
What's the deal? BistosDealroom has a profile for this one. Try Dealroom →, a Korean maker of biosignal medical diagnostic devices, raised US$2.93M in a post-IPO equity round in June 2026. Its largest shareholder, CU Medical SystemDealroom has a profile for this one. Try Dealroom →, took the entire third-party allocation. The company earmarked US$2.1M for facilities and roughly US$838.4K for operations.
Why now? Bistos shares, above US$5.03 early this year, slid to the 2,000-won range, pushing its market value below the US$12.6M minimum for staying listed. From July 2026, that threshold rises to US$16.8M, raising the stakes on defending the share price.
What's the endgame? CU Medical System acquired a 33.88% stake in Bistos in January 2026, aiming to build a full-line medical device firm. The plan combines Bistos's class 1 and 2 patient-monitoring technology with CU Medical's class 3 heart defibrillator business.
The shareholder's cash injection followed Bistos signing a US$1.68M treasury-stock trust contract to stabilise the price. Days earlier, on July 6 2026, Bistos exercised a call option to repurchase US$838.4K of the US$3.35M convertible bond it issued in March 2026, planning to cancel it and cut potential dilution.
What could go wrong? The March 2026 bond drew scrutiny: US$1.68M was routed into Tway Air perpetual convertible bonds, unrelated to Bistos's core business, with CU Medical System guaranteeing up to 130% of the principal. CU Medical System's own history compounds concern — it issued convertible bonds eight times in 2019, and weak results later left creditors seeking early buybacks.
The signal: Bistos has swapped a debt-raising strategy for a share-price defence, and analysts say it has put out the immediate fire. But financial fixes alone won't hold. "If financial responses keep repeating without business results, the price-defence effect can only be temporary," one securities industry official said, adding that operational synergy and earnings will decide whether market trust returns.
Read more: Edaily
Image credit: Rennett Stowe
